
Chinese authorities have sacked the researcher who led an experimental gene-editing trial that resulted in the death of a child. An investigation into the trial by the Shanghai municipal government found that the researcher and his team failed to follow regulations and overlooked warning signs in a safety report. Several others involved in the case have also been punished.

Two children died from gene therapies in China: where the field goes next
In July, the journal Science and the website Retraction Watch jointly reported that Zilong Qiu, a neuroscientist at Shanghai Jiao Tong University School of Medicine, led a team that developed an experimental gene-editing therapy for a six-year-old girl with a rare neurodevelopmental disorder called Snijders Blok–Campeau syndrome. The therapy was carried by a viral vector that was injected into the girl’s spine and then travelled to her brain. The girl died of medical complications after receiving the therapy at Xinhua Hospital, also in Shanghai, in March 2025.
The institutions involved in the trial — Shanghai Jiao Tong University School of Medicine and Xinhua Hospital — have also been reprimanded and instructed to examine their own practices. “I expect the action to send a big warning to research institutes and hospitals across the country,” says Jiayou Shi, a lawyer at the National Research Center for Civil and Commercial Law at Renmin University of China in Beijing.
The trial was conducted under China’s fast-track pathway, called investigator-initiated trials (IITs). IITs allow researchers and biotech companies to test therapies quickly in hospitals without supervision from the country’s regulators. The Chinese government increased oversight of these trials in May, which Shi says should prevent similar cases in future.
Lizzi Lee, who studies China’s economic and technological policies at the Asia Society Policy Institute, a think tank in New York City, says the trial is “a cautionary tale” for the country’s rapidly growing biotechnology industry. There is real momentum in the industry in China, but clinical oversight hasn’t always kept pace, Lee says. “The investigation is quite candid about what went wrong,” adds Lee.
Key findings
According to a statement released through China’s state-run media on 13 November, the Shanghai government’s investigation found that Qiu was the main person responsible for the research. He has been sacked from his position as the deputy director of the Songjiang Research Institution, which is affiliated with Shanghai Jiao Tong University School of Medicine. Another member of Qiu’s team, a deputy researcher at Xinhua Hospital, has also been dismissed. Both researchers have been barred from leading or participating in science projects for five years and have been added to a national database of people and organizations that have committed serious breaches of research integrity.
About a month before the girl received the experimental therapy, Qiu’s team received results from a preclinical toxicology study showing that monkeys sustained liver damage, according to Science and Retraction Watch. Investigators found that Qiu’s team failed to inform the researcher in charge of the clinical research at Xinhua Hospital in a timely fashion about the results of the primate experiment, which meant “the early warning signal” in the safety report was not “given high attention”, according to the statement. The clinical researcher has been removed as head of research at Xinhua Hospital. Qiu did not respond to questions about the investigation report.
Shi says the trial in the girl should not have gone ahead if the therapy showed evidence of harm in animals.
The investigators also found that Xinhua Hospital failed to conduct sufficient scientific assessment for the clinical trial. According to the statement, although the hospital’s ethics committee asked the research team to submit extra materials when safety evidence was lacking, it approved the trial without receiving those materials. In addition, the consent form given to the children’s family did not mention death as a risk of taking the therapy. Two members of the hospital’s ethics committee were given penalties.
Shanghai Jiao Tong University School of Medicine and Xinhua Hospital did not respond to questions about the investigation report.
Preclinical study
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research